MCID: DRM009
MIFTS: 29

Dermatomycosis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatomycosis

MalaCards integrated aliases for Dermatomycosis:

Name: Dermatomycosis 12 15
Dermatomycoses 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1563
ICD9CM 35 111 111.9
MeSH 44 D003881
SNOMED-CT 68 14560005 47382004
UMLS 73 C0011630

Summaries for Dermatomycosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in skin or of its appendages, has material basis in Ascomycota fungi other than the dermatophytes.

MalaCards based summary : Dermatomycosis, also known as dermatomycoses, is related to eumycotic mycetoma and superficial mycosis. An important gene associated with Dermatomycosis is RPS3 (Ribosomal Protein S3). The drugs Ciclopirox and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thymus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 A dermatomycosis is a skin disease caused by a fungus. This excludes... more...

Related Diseases for Dermatomycosis

Graphical network of the top 20 diseases related to Dermatomycosis:



Diseases related to Dermatomycosis

Symptoms & Phenotypes for Dermatomycosis

GenomeRNAi Phenotypes related to Dermatomycosis according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.4 RPS3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.4 ZBTB22
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.4 ZBTB22
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.4 RPS3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.4 RPS3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.4 RPS3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.4 RPS3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.4 RPS3 ZBTB22
9 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.4 ZBTB22
10 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.4 ZBTB22
11 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.4 ZBTB22

Drugs & Therapeutics for Dermatomycosis

Drugs for Dermatomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29342-05-0 2749
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
6
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
7
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
8
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65277-42-1 3823 47576
9
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60628-96-8 2378
10
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 1549008 5402
11
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
12
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 47641 73342
13
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
14
Itraconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84625-61-6 55283
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
16
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
17
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
18
deoxycholic acid Approved Phase 4,Phase 3,Phase 2 83-44-3 222528
19
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2 235114-32-6 3081921 477468
20
Omalizumab Approved, Investigational Phase 4 242138-07-4
21 Keratolytic Agents Phase 4,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Ulcer Agents Phase 4,Phase 1
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antacids Phase 4,Phase 1
36 Proton Pump Inhibitors Phase 4,Phase 1
37 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Liposomal amphotericin B Phase 4,Phase 3,Phase 2
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Echinocandins Phase 4,Phase 3,Phase 2,Phase 1
42 Respiratory System Agents Phase 4,Phase 2,Phase 3
43 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3
44
Hydroxyitraconazole Phase 4,Phase 2,Phase 3,Phase 1
45 Antitussive Agents Phase 4
46 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
47 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Phase 2
48 Antibodies Phase 4,Phase 1
49 Anti-Allergic Agents Phase 4,Phase 2,Phase 3
50 Immunoglobulin E Phase 4

Interventional clinical trials:

(show top 50) (show all 340)
# Name Status NCT ID Phase Drugs
1 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
3 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
4 Voriconazole for IPA in Chinese Patients With COPD Unknown status NCT02234739 Phase 4 Voriconazole
5 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
6 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
7 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
8 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
9 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
10 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
11 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
12 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Completed NCT00334412 Phase 4 Ambisome;caspofungin
13 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
14 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
15 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
16 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
17 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
18 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
19 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
20 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
21 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
22 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
23 Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
24 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
25 CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
26 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
27 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
28 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
29 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
30 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
31 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
32 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
33 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
34 Amphotericin-B and Voriconazole for Pulmonary Blastomycosis Suspended NCT02283905 Phase 4 amphotericin-B;voriconazole
35 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
36 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
37 Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Terminated NCT02646774 Phase 4 Micafungin
38 Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
39 An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
40 A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
41 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
42 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis Unknown status NCT01125644 Phase 3 SPK-843
43 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Unknown status NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
44 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
45 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
46 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
47 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
48 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
49 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
50 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo

Search NIH Clinical Center for Dermatomycosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dermatomycoses

Genetic Tests for Dermatomycosis

Anatomical Context for Dermatomycosis

MalaCards organs/tissues related to Dermatomycosis:

41
Skin, Testes, Thymus

Publications for Dermatomycosis

Articles related to Dermatomycosis:

(show top 50) (show all 295)
# Title Authors Year
1
Dermatomycoses Due to Nannizzia praecox (Formerly Microsporum praecox) in Germany: Case Reports and Review of the Literature. ( 29067631 )
2018
2
<i>In Vitro</i> Antifungal Activity of Hexahydropyrimidine Derivatives against the Causative Agents of Dermatomycosis. ( 29226215 )
2017
3
Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). ( 28757272 )
2017
4
SIXTEEN YEARS OF DERMATOMYCOSIS CAUSED BY Candida spp. IN THE METROPOLITAN AREA OF PORTO ALEGRE, SOUTHERN BRAZIL. ( 27007557 )
2016
5
Dermatomycosis due to Neoscytalidium spp. ( 27296436 )
2016
6
Oral Antifungal Drugs in the Treatment of Dermatomycosis. ( 27251319 )
2016
7
Dermatomycosis caused by Paranannizziopsis australasiensis in five tuatara (Sphenodon punctatus) and a coastal bearded dragon (Pogona barbata) in a zoological collection in New Zealand. ( 27074995 )
2016
8
Dermatomycosis in three central bearded dragons (Pogona vitticeps) associated with Nannizziopsis chlamydospora. ( 26951329 )
2016
9
Sample Taking and Direct Examination in Dermatomycoses. ( 26534894 )
2016
10
An epidemiological study of animals dermatomycoses in Iran. ( 27180290 )
2016
11
Dermatomycosis frequency and localization sites. ( 25870481 )
2015
12
Epidemiological and clinical pattern of dermatomycoses in rural India. ( 25657132 )
2015
13
Dermatomycoses and inflammation: The adaptive balance between growth, damage, and survival. ( 25662199 )
2015
14
Immunoresponses in dermatomycoses. ( 25736316 )
2015
15
Comparison of modified Chicago sky blue stain and potassium hydroxide mount for the diagnosis of dermatomycoses and onychomycoses. ( 25765148 )
2015
16
Mycology - an update Part 3: Dermatomycoses: topical and systemic therapy. ( 25918080 )
2015
17
Mycological Pattern of Dermatomycoses in a Tertiary Care Hospital. ( 26491453 )
2015
18
Dermatomycosis. ( 25231229 )
2014
19
Clinical evaluation of a novel commercial multiplex-based PCR diagnostic test for differential diagnosis of dermatomycoses. ( 23734586 )
2014
20
In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes. ( 24215461 )
2014
21
Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. ( 24533779 )
2014
22
Dermatomycoses: challenges and human immune responses. ( 24818759 )
2014
23
Mycology - an update part 2: dermatomycoses: clinical picture and diagnostics. ( 25176455 )
2014
24
Identification and antifungal susceptibility of fungi isolated from dermatomycoses. ( 23556501 )
2014
25
Species distribution and phospholipase activity of fungi isolated from children with dermatomycosis from child day care units in Natal, Brazil. ( 23279304 )
2013
26
Successfully treated dermatomycosis in California sea lions (Zalophus californianus). ( 23805567 )
2013
27
Dermatomycosis in lower limbs of diabetic patients followed by podiatry consultation. ( 23147514 )
2013
28
The benefits of combination therapy in dermatomycoses. ( 23574018 )
2013
29
Isoconazole nitrate: a unique broad-spectrum antimicrobial azole effective in the treatment of dermatomycoses, both as monotherapy and in combination with corticosteroids. ( 23574019 )
2013
30
Prevalence of dermatomycosis in a Brazilian tertiary care hospital. ( 22936103 )
2012
31
Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. ( 22233283 )
2012
32
First case of subcutaneous dermatomycoses in a Tunisian renal transplant patient. ( 22407643 )
2012
33
Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis. ( 22735222 )
2012
34
Geotrichum candidum as etiological agent of horse dermatomycosis. ( 20970928 )
2011
35
In vitro antifungal activity of dihydroxyacetone against causative agents of dermatomycosis. ( 20936361 )
2011
36
A 5-year survey of dermatomycoses in southwest Poland, years 2003-2007. ( 19925570 )
2011
37
Practical tip: Chicago Sky Blue (CSB) stain can be added to the routine potassium hydroxide (KOH) wet-mount to provide a color contrast and facilitate the diagnosis of dermatomycoses. ( 21906491 )
2011
38
Scopulariopsis brevicaulis as the cause of dermatomycosis. ( 20361882 )
2010
39
Updating corneofungimetry: a bioassay exploring dermatomycoses and antifungal susceptibility. ( 19644764 )
2010
40
Historical aspects of dermatomycoses. ( 20347652 )
2010
41
Dermatomycosis in a pet inland bearded dragon (Pogona vitticeps) caused by a Chrysosporium species related to Nannizziopsis vriesii. ( 19659541 )
2009
42
Dermatomycosis caused by common and rare fungi in Mumbai. ( 18797079 )
2008
43
Dermatomycosis in renal transplant recipients in Adana, Turkey. ( 18937667 )
2008
44
Dermatomycosis, hyperhydrosis, and mechanical injury to skin of the feet in Croatian soldiers during war in Croatia 1991-1992. ( 18751600 )
2008
45
Childhood dermatomycoses study in Sfax Hospital, Tunisia. ( 18498308 )
2008
46
Clinicopathologic presentations of dermatomycoses in cancer patients. ( 18503529 )
2008
47
Antifungal activity of the essential oil of Thymus vulgaris L. and thymol on experimentally induced dermatomycoses. ( 18651285 )
2008
48
Superficial dermatomycoses worldwide: multinational treatment experience with a combination of isoconazole nitrate and diflucortolone valerate. Introduction. ( 18783558 )
2008
49
The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses. ( 18783560 )
2008
50
New contrast stain for the rapid diagnosis of dermatophytic and candidal dermatomycoses. ( 18794476 )
2008

Variations for Dermatomycosis

Expression for Dermatomycosis

Search GEO for disease gene expression data for Dermatomycosis.

Pathways for Dermatomycosis

GO Terms for Dermatomycosis

Molecular functions related to Dermatomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 8.96 DNM1 RPS3
2 kinase binding GO:0019900 8.62 CHIA RPS3

Sources for Dermatomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....